Vuno Registers Japanese Patent for Advanced DeepCAS Technology

Medical AI company VUNO announced on the 19th that a patent related to the advancement of its AI-based cardiac arrest risk monitoring medical device VUNO Med®-DeepCARS® (hereinafter DeepCARS), titled ‘Prediction method using artificial neural networks in environments with limited input variables,’ has been granted in Japan.

The patent registered in Japan involves a technology that uses a graph neural network model (GNN) trained based on the relationships between input variables to detect the risk of cardiac arrest in hospitalized patients, enabling accurate and consistent predictions even in environments with limited input variables.

Applying this technology to the DeepCARS product or new prognostic prediction solutions eliminates the need to develop separate models tailored to each hospital. In actual medical settings, measurement data vary depending on the patient’s condition, location of stay, and the hospital where they are admitted.

For example, intensive care unit patients have various measurement data including blood test results, whereas general ward inpatients may not. Some blood tests, such as arterial blood gas analysis (ABGA) and tests indicating shock (Lactate), are performed only on a very small portion of general ward inpatients. These tests are far from the information typically collected for all patients in general wards. Even if the data available varies depending on the situation, efficient prediction is possible through the graph neural network model training process enabled by this technology.

By utilizing the patented technology developed by VUNO, accurate predictions can be made by AI algorithms even when there are missing values (uncollected data) depending on the hospital’s circumstances. A deep learning model trained using vital signs such as blood pressure and pulse along with blood test data can function as an accurate model equivalent to having blood test results at the actual prediction time, even without blood test data input.

Yehah Lee, CEO of VUNO, stated, "The patent registration is the first step for DeepCARS’ entry into the Japanese market," and added, "DeepCARS is preparing for full-scale global market entry while undergoing the approval process with the U.S. Food and Drug Administration (FDA)." She further said, "We will continue to strive tirelessly so that VUNO’s solutions can be of help to many people in medical settings around the world."

DeepCARS was the first in the domestic medical AI industry to receive the U.S. FDA Breakthrough Device Designation (BDD) last year. Establishing itself as an essential medical tool in domestic medical settings, the cumulative number of hospitals billing for the service surpassed 100 as of early last month.

This content was produced with the assistance of AI translation services.